A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ
A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ
Posted by on 2022-08-12
Communications Biology - The co-crystal berberine-ibuprofen is an effective agent for treating obesity through a reduction of the activity of the non-canonical I κB kinases, IKKε and TBK1.
